Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

A Study of AK129 in Patients With Advanced Malignant Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Tumors(Stage IA-IB)

Interventions: Drug: AK129 IV infusion

First Posted Date: 2022-12-09

Last Posted Date: 2023-09-21

Lead Sponsor: Akeso

Target Recruit Count: 182

Registration Number: NCT05645276

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Phase 1

Recruiting

Conditions: NSCLC

Interventions: Drug: AK119
Drug: AK112
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2022-12-05

Last Posted Date: 2023-03-09

Lead Sponsor: Akeso

Target Recruit Count: 114

Registration Number: NCT05636267

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: AK119
Drug: AK104

First Posted Date: 2022-09-29

Last Posted Date: 2022-12-30

Lead Sponsor: Akeso

Target Recruit Count: 102

Registration Number: NCT05559541

Locations: 🇨🇳
Tianjin Medical University Cancer Insitute & Hospital, Tianjin, Tianjin, China

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Phase 1

Completed

Conditions: Healthy Male Subjects

Interventions: Drug: AK104 (after the change)
Drug: AK104 (before the change)

First Posted Date: 2022-09-29

Last Posted Date: 2024-05-16

Lead Sponsor: Akeso

Target Recruit Count: 100

Registration Number: NCT05559554

Locations: 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China

Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: AK101 injection SC

First Posted Date: 2022-08-22

Last Posted Date: 2024-06-04

Lead Sponsor: Akeso

Target Recruit Count: 950

Registration Number: NCT05509361

Locations: 🇨🇳
Peking university people's hospital, Beijing, China

A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: SCLC,Extensive Stage

Interventions: Drug: AK104 IV infusion；Chiauranib oral

First Posted Date: 2022-08-18

Last Posted Date: 2024-05-24

Lead Sponsor: Akeso

Target Recruit Count: 36

Registration Number: NCT05505825

Locations: 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇦🇺
Sunshine Hospital, St Albans, Victoria, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia

and more 4 locations

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Placebo
Drug: AK111

First Posted Date: 2022-08-17

Last Posted Date: 2022-08-17

Lead Sponsor: Akeso

Target Recruit Count: 48

Registration Number: NCT05504317

Locations: 🇨🇳
AkesoBio Investigative Site 1002, Bengbu, Anhui, China
🇨🇳
AkesoBio Investigative Site 1001, Beijing, China

AK112 in Advanced Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Advanced Non-small-cell Lung Cancer

Interventions: Drug: AK112
Drug: Pembrolizumab

First Posted Date: 2022-08-12

Last Posted Date: 2023-09-21

Lead Sponsor: Akeso

Target Recruit Count: 398

Registration Number: NCT05499390

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Phase 3

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: placebo
Biological: AK104

First Posted Date: 2022-08-05

Last Posted Date: 2022-08-05

Lead Sponsor: Akeso

Target Recruit Count: 405

Registration Number: NCT05489289

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Phase 2

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: AK111
Biological: Placebo

First Posted Date: 2022-07-21

Last Posted Date: 2024-03-06

Lead Sponsor: Akeso

Target Recruit Count: 125

Registration Number: NCT05467995

Locations: 🇨🇳
The first affiliated hospital of Bengbu medical college, Bengbu, Anhui, China
🇨🇳
Peking university people's hospital, Beijing, Beijing, China
🇨🇳
Peking University Shougang hospital, Beijing, Beijing, China

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy